A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Single and Multiple Doses of MT-7117 in Chinese Healthy Subjects
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Dersimelagon (Primary)
- Indications Diffuse scleroderma; Erythropoietic protoporphyria
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
Most Recent Events
- 02 Jun 2025 New trial record